NCT06189508View on ClinicalTrials.gov

A Study to Evaluate Single Subcutaneous Doses of NXT007 Among Injection Sites Abdomen, Upper Arm, and Thigh in Healthy Male Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

February 14, 2024

Primary Completion Date

December 22, 2024

Study Completion Date

December 22, 2024

Conditions
Healthy Male Participants
Interventions
DRUG

NXT007

In all groups, the NXT007 single dose administration will occur in the morning of Day 1 under fasted conditions. Study treatment will occur via the route of administration and at the site of injection specified for each group.

Trial Locations (2)

1010

New Zealand Clinical Research - Auckland, Auckland

8011

New Zealand Clinical Research - Christchurch, Christchurch

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT06189508 - A Study to Evaluate Single Subcutaneous Doses of NXT007 Among Injection Sites Abdomen, Upper Arm, and Thigh in Healthy Male Participants | Biotech Hunter | Biotech Hunter